Impact of estradiol-valerate/dienogest on work productivity and activities of daily living in European and Australian women with heavy menstrual bleeding

Radoslaw Wasiak, Anna Filonenko, David J Vanness, Kim U Wittrup-Jensen, Donald E Stull, Steven Siak, Ian Fraser, Radoslaw Wasiak, Anna Filonenko, David J Vanness, Kim U Wittrup-Jensen, Donald E Stull, Steven Siak, Ian Fraser

Abstract

Background: The purpose of this study was to quantify the impact of estradiol-valerate/dienogest (E(2)V/DNG; Qlaira(®)/Natazia(®)) on work productivity and activities of daily living in European and Australian women with heavy menstrual bleeding.

Methods: Women aged 18-54 years with a confirmed diagnosis of heavy menstrual bleeding and no recognizable pathology were recruited across nine European countries (the Czech Republic, Finland, Germany, Hungary, The Netherlands, Poland, Sweden, UK, and Ukraine) and Australia. The women were randomized to receive either E(2)V/DNG (n = 149) or placebo (n = 82) for seven treatment cycles (196 days). The outcomes assessed included work productivity (ie, productivity while at work) and activities of daily living, measured on a Likert scale from 0 to 10 (with higher values denoting higher impairment levels) at baseline and at the end of the third and seventh cycles (days 84 and 196). The equivalent monetary value associated with the changes in work productivity and activities of daily living was also calculated.

Results: Across all the countries, greater improvements from baseline to the end of treatment were observed with E(2)V/DNG treatment than placebo in work productivity (46.0% versus 15.1%) and activities of daily living (55.6% versus 30.8%). In 2008, savings associated with improvements in work productivity and activities of daily living due to E(2)V/DNG treatment (net of placebo improvement) were estimated to be between US$22-62 and US$18-56 per month (in purchasing power parity of US$), respectively.

Conclusion: E(2)V/DNG has a consistent positive impact on work productivity and activities of daily living in European and Australian women with heavy menstrual bleeding. These improvements were associated with a reduction in monetary burden of heavy menstrual bleeding compared with the placebo group, consistent with the response to treatment observed.

Keywords: activities of daily living; dienogest; estradiol valerate; heavy menstrual bleeding; work productivity.

Figures

Figure 1
Figure 1
Work productivity impairment values at baseline and EOT as measured using the modified Work Productivity and Activity Impairment (mWPAI) questionnaire. Note: Value of “0” indicate no impairment due to heavy menstrual bleeding and value of “10” indicate complete work productivity impairment (ie, prevents undertaking any work). Abbreviation: EOT, end of treatment; AUS, Australia; CZR, Czech Republic; FIN, Finland; GER, Germany; HUN, Hungary; NL, The Netherlands; PL, Poland; SWE, Sweden; UK, United Kingdom; UKR, Ukraine.
Figure 2
Figure 2
Activities of daily living impairment values at baseline and EOT as measured using the modified Work Productivity and Activity Impairment (mWPAI) questionnaire. Note: Value of “0” indicate no impairment due to HMB and value of “10” indicate complete impairment of activities of daily living (ie, prevents undertaking any usual activities). Abbreviations: EOT, end of treatment; E2V/DNG, estradiol-valerate/dienogest; AUS, Australia; CZR, Czech Republic; FIN, Finland; GER, Germany; HUN, Hungary; NL, The Netherlands; PL, Poland; SWE, Sweden; UK, United Kingdom; UKR, Ukraine.
Figure 3
Figure 3
Reduction in work productivity and activities of daily living impairment across all countries (baseline to end of treatment) by treatment group (negative values indicate improvement). Abbreviation: E2V/DNG, estradiol-valerate/dienogest.

References

    1. National Institute for Clinical Excellence. Heavy Menstrual Bleeding Costing report: Implementing NICE guidance in England. 2007. [Accessed October 9, 2009]. Available from: .
    1. National Collaborating Centre for Women’s and Children’s Health. Heavy Menstrual Bleeding. Clinical Guideline. National Institute for Health and Clinical Excellence. London, UK: RCOG Press; 2007.
    1. National Institute for Clinical Excellence. Technology Appraisal 78. London, UK: National Institute for Clinical Excellence; 2004. Fluid-filled Thermal Balloon and Microwave Endometrial Ablation Techniques for Heavy Menstrual Bleeding.
    1. Fraser IS, Langham S. Health-related quality of life and economic burden of abnormal uterine bleeding. Expert Rev Obstet Gynecol. 2009;4(2):179–189.
    1. Liu Z, Doan QV, Blumenthal P, Dubois RW. A systematic review evaluating health-related quality of life, work impairment, and healthcare costs and utilization in abnormal uterine bleeding. Value Health. 2007;10(3):183–194.
    1. ACOG Practice Bulletin. Clinical management guidelines for obstetrician- gynecologists. Number 81, May 2007. Obstet Gynecol. 2007;109(5):1233–1248.
    1. Amann M, Anguino H, Bauman RA, et al. Chronic Abnormal Uterine Bleeding in Nongravid Women. Pasadena, CA: Kaiser Permanente Southern California; 2006.
    1. Vilos GA, Lefebvre G, Graves GR. SOGC Clinical practice guidelines: guidelines for the management of abnormal uterine bleeding. J Obstet Gynaecol Can. 2001;23(8):704–709.
    1. Clarke J. Treatment of heavy menstrual bleeding. BMJ. 2010;341:c3771.
    1. Fraser IS, Romer T, Parke S, et al. Effective treatment of heavy and/or prolonged menstrual bleeding with an oral contraceptive containing estradiol valerate and dienogest: a randomized, double-blind Phase III trial. Hum Reprod. 2011;26(10):2698–2708.
    1. Jensen JT, Parke S, Mellinger U, Machlitt A, Fraser IS. Effective treatment of heavy menstrual bleeding with estradiol valerate and dienogest: a randomized controlled trial. Obstet Gynecol. 2011;117(4):777–787.
    1. Reilly Associates. Work productivity and activity impairment questionnaire scoring. 2002. [Accessed March 3, 2011]. Available from: .
    1. WinBUGs. [Accessed May 3, 2012]. Available from: .
    1. Spiegelhalter DJ, Best NG, Carlin BP, Van der Linde A. Bayesian measures of model complexity and fit. J R Stat Soc Ser B Stat Soc. 2002;64(4):583–616.
    1. Wasiak R, Filonenko A, Stull DE, et al. Methodological considerations in impact assessment of estradiol valerate/dienogest (E2V/DNG, Qlaira®) on work productivity (WP) and activities of daily living (ADL) outcomes in multinational clinical trials in heavy and/or prolonged menstrual bleeding (HPMB). Presented at the 13th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research; Prague, Czech Republic. November 6–9, 2010.
    1. United Nations Statistics Division. Purchasing power parities (PPP) conversion factor, local currency unit to international dollar. Millennium development goals indicators. 2010. [Accessed March 3, 2011]. Available from: .
    1. Frick KD, Clark MA, Steinwachs DM, et al. Financial and quality-of-life burden of dysfunctional uterine bleeding among women agreeing to obtain surgical treatment. Womens Health Issues. 2009;19(1):70–78.
    1. el Senoun GS, Mousa HA, Mahmood TA. Medium-term follow-up of women with menorrhagia treated by rollerball endometrial ablation. Acta Obstet Gynecol Scand. 2000;79(10):879–883.
    1. Goldrath MH. Evaluation of hydrothermablator and rollerball endometrial ablation for menorrhagia 3 years after treatment. J Am Assoc Gynecol Laparosc. 2003;10(4):505–511.
    1. Loffer FD. Three-year comparison of thermal balloon and rollerball ablation in treatment of menorrhagia. J Am Assoc Gynecol Laparosc. 2001;8(1):48–54.
    1. Mousa HA, Abou El Senoun GM, Mahmood TA. Medium-term clinical outcome of women with menorrhagia treated by rollerball endometrial ablation versus abdominal hysterectomy with conservation of at least one ovary. Acta Obstet Gynecol Scand. 2001;80(5):442–446.
    1. Sambrook AM, Bain C, Parkin DE, Cooper KG. A randomised comparison of microwave endometrial ablation with transcervical resection of the endometrium: follow up at a minimum of 10 years. BJOG. 2009;116(8):1033–1037.
    1. Sculpher MJ, Dwyer N, Byford S, Stirrat GM. Randomised trial comparing hysterectomy and transcervical endometrial resection: effect on health related quality of life and costs two years after surgery. Br J Obstet Gynaecol. 1996;103(2):142–149.
    1. Abel U, Koch A. The role of randomization in clinical studies: myths and beliefs. J Clin Epidemiol. 1999;52(6):487–497.
    1. Fleurence RL, Naci H, Jansen JP. The critical role of observational evidence in comparative effectiveness research. Health Aff (Millwood) 2010;29(10):1826–1833.

Source: PubMed

Sponsorer och medarbetare

Medicinska tillstånd

Läkemedelsinterventioner

3
Prenumerera